Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

223Ra

  • <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study)
    Open Access
    177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
    Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Kim M. Pabst, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor
    Journal of Nuclear Medicine December 1, 2023, 64 (12) 1925-1931; DOI: https://doi.org/10.2967/jnumed.123.266125
  • <sup>68</sup>Ga-PSMA PET/CT for Response Evaluation of <sup>223</sup>Ra Treatment in Metastatic Prostate Cancer
    You have access
    68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
    Anouk C. de Jong, Marcel Segbers, Sui Wai Ling, Laura H. Graven, Niven Mehra, Paul Hamberg, Tessa Brabander, Ronald de Wit and Astrid A.M. van der Veldt
    Journal of Nuclear Medicine October 1, 2023, 64 (10) 1556-1562; DOI: https://doi.org/10.2967/jnumed.123.265489
  • Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>223</sup>Ra: PARABO, a Prospective, Noninterventional Study
    Open Access
    Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study
    Holger Palmedo, Hojjat Ahmadzadehfar, Susanne Eschmann, Andreas Niesen, Johann Schönberger, Vahé Barsegian, Knut Liepe, Felix M. Mottaghy, Rongjin Guan, Joerg Pinkert, Per Sandström and Ken Herrmann
    Journal of Nuclear Medicine September 1, 2023, 64 (9) 1392-1398; DOI: https://doi.org/10.2967/jnumed.123.265557
  • Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study
    Open Access
    Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
    Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 574-578; DOI: https://doi.org/10.2967/jnumed.122.264456
  • You have access
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
    Michael C. Bellavia, Ravi B. Patel and Carolyn J. Anderson
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1636-1641; DOI: https://doi.org/10.2967/jnumed.122.264373
  • <sup>223</sup>Ra Induces Transient Functional Bone Marrow Toxicity
    You have access
    223Ra Induces Transient Functional Bone Marrow Toxicity
    Maria Parlani, Francesco Boccalatte, Anna Yeaton, Feng Wang, Jianhua Zhang, Iannis Aifantis and Eleonora Dondossola
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1544-1550; DOI: https://doi.org/10.2967/jnumed.121.263310
  • Enhancing <sup>223</sup>Ra Treatment Efficacy by Anti-<strong>β</strong>1 Integrin Targeting
    You have access
    Enhancing 223Ra Treatment Efficacy by Anti-β1 Integrin Targeting
    Claudia Paindelli, Stefano Casarin, Feng Wang, Luis Diaz-Gomez, Jianhua Zhang, Antonios G. Mikos, Christopher J. Logothetis, Peter Friedl and Eleonora Dondossola
    Journal of Nuclear Medicine July 1, 2022, 63 (7) 1039-1045; DOI: https://doi.org/10.2967/jnumed.121.262743
  • <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
    Open Access
    177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
    Oliver Sartor, Christian la Fougère, Markus Essler, Samer Ezziddin, Gero Kramer, Jörg Ellinger, Luke Nordquist, John Sylvester, Giovanni Paganelli, Avivit Peer, Martin Bögemann, Jeffrey Meltzer, Per Sandström, Frank Verholen and Daniel Y. Song
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 410-414; DOI: https://doi.org/10.2967/jnumed.121.262240
  • Improved <sup>223</sup>Ra Therapy with Combination Epithelial Sodium Channel Blockade
    Open Access
    Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
    Diane S. Abou, Amanda Fears, Lucy Summer, Mark Longtine, Nadia Benabdallah, Ryan C. Riddle, David Ulmert, Jeff M. Michalski, Richard L. Wahl, Denise Chesner, Michele Doucet, Nicholas C. Zachos, Brian W. Simons and Daniel L.J. Thorek
    Journal of Nuclear Medicine December 1, 2021, 62 (12) 1751-1758; DOI: https://doi.org/10.2967/jnumed.121.261977
  • The Prognostic Value of Quantitative Bone SPECT/CT Before <sup>223</sup>Ra Treatment in Metastatic Castration-Resistant Prostate Cancer
    You have access
    The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer
    Helmut Dittmann, Sabine Kaltenbach, Matthias Weissinger, Francesco Fiz, Peter Martus, Maren Pritzkow, Juergen Kupferschlaeger and Christian la Fougère
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 48-54; DOI: https://doi.org/10.2967/jnumed.119.240408

Pages

  • Next
  • 1
  • 2
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire